Neeraj Agarwal: Striking Results in JCO from Ph2b SunRISe-1 Trial
Neeraj Agarwal, Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute (HCI), shared a post on X:
“Congrats, Sia Daneshmand and Andrea Necchi.
Striking results in JCO from Ph2b SunRISe-1 trial in patients with BCG-unresponsive high-risk NMIBC bladder cancer treated with TAR-200 monoRx ~83% CR, with >2 yrs median response, ~13% Grade ≥3 TRAEs”
Tian Zhang, Director of Clinical Research at UT Southwestern Medical Center, shared Neeraj Agarwal‘s post on X, adding:
“Great to see 83% CR for TAR-200 treating non-muscle invasive bladder cancer in Sunrise-1!
Congrats, Sia Daneshmand and Andrea Necchi, and teams!”
Sumanta K. Pal, Vice Chair of Academic Affairs at City of Hope, shared Neeraj Agarwal‘s post, adding:
“Congrats Sia Daneshmand and Andrea Necchi and study team on this terrific work. Trying to keep up with all of the advances for intravesical therapy for bladder cancer!
Just amazing.”
Title: TAR-200 for Bacillus Calmette-Guérin–Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study
Journal: JCO
Authors: Siamak Daneshmand, Michiel S. Van der Heijden, Joseph M. Jacob, Felix Guerrero-Ramos, Martin Bögemann, Giuseppe Simone, Christopher M. Pieczonka, Nelson Canales Casco, Daniel Zainfeld, Philipp Spiegelhalder, Evanguelos Xylinas, David Cahn, Yair Lotan, Katie S. Murray, Takashi Kawahara, Katharine Stromberg, Jason Martin, Abhijit Shukla, Christopher J. Cutie, Kristi Bertzos, Shalaka Hampras, Hussein Sweiti, Andrea Necchi
More posts featuring Neeraj Agarwal and Tian Zhang on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023